Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Objectives: This study aimed to investigate the hypothalamic-pituitary-gonadal axis in a sample of male patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain and the presence of osteopaenia and/or osteoporosis in those diagnosed with hypogonadism. Design: Observational study using health data routinely collected for non-research purposes. Setting: Department of Pain Management, Russells Hall Hospital, Dudley, UK. Patients: Twenty consecutive male patients attending follow-up clinics for intrathecal opioid therapy had the gonadal axis evaluated by measuring their serum luteinising hormone, follicle stimulating hormone, total testosterone, sex hormone binding globulin and calculating the free testosterone level. Bone mineral density was measured by DEXA scanning in those patients diagnosed with hypogonadism. Results: Based on the calculated free testosterone concentrations, 17 (85%) patients had biochemical hypogonadism with 15 patients (75%) having free testosterone <180 pmol/L and 2 patients (10%) between 180 and 250 pmol/L. Bone mineral density was assessed in 14 of the 17 patients after the exclusion of 3 patients. Osteoporosis (defined as a T score ≤−2.5 SD) was detected in three patients (21.4%) and osteopaenia (defined as a T score between −1.0 and −2.5 SD) was observed in seven patients (50%). Five of the 14 patients (35.7%) were at or above the intervention threshold for hip fracture. Conclusions: This study suggests an association between hypogonadism and low bone mass density in patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain. Surveillance of hypogonadism and the bone mineral density levels followed by appropriate treatment may be of paramount importance to reduce the risk of osteoporosis development and prevention of fractures in this group of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a small observational study comprising 20 males receiving long-term intrathecal opioid treatment for nonmalignant bone pain, 17 patients displayed biochemical hypogonadism”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [147]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, high PRL levels were found in 2 of 20 (10%) noncancer pain patients on intrathecal morphine (147).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [147]
The cited source says what the claim attributes to it.
In the citing paper
“whereas 10 of hypogonadal patients had osteopenia or osteoporosis (147).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
Johnell, O., & Kanis, J. A. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0172-4 · Cited by 4,704
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 2×
“Calculations of free testosterone (FT) were carried out using the Vermeulen equation.(15) Serum TT <8 nmol/L and/or FT <180 pmol/L was considered as biochemical hypogonadism.”
BackgroundMethodLongitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760 · cited 1×
“Of the possible chronic illnesses identified in a longitudinal study with 890 male participants, only cancer (9%) was associated with a greater decrease in testosterone levels than the decrease that occurred with ageing alone.(38) Women were not included in this study.”
BackgroundFRAX™ and the assessment of fracture probability in men and women from the UK
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., & McCloskey, E. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0543-5 · Cited by 2,467 · cited 1×
“The 10-year probability of fracture was calculated based on the Fracture Risk Assessment Tool (FRAX).(19) In addition to the BMD value or T score (femoral neck), this tool takes into account clinical risk factors for the development of osteoporotic or hip fractures such as previous fractures, a history of hip fracture…”
Diagnosis of osteoporosis and assessment of fracture risk
Kanis, J. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08761-5 · Cited by 2,260 · cited 3×
“Low bone mass is an important component of the risk of fracture as well as non-skeletal factors such as the propensity to fall.(16) 28 Many fragility fractures occur in the absence of osteoporosis, although in the presence of this disease, the risk of fracture is higher.”
BackgroundInfluentialMortality after all major types of osteoporotic fracture in men and women: an observational study
Center, J. R., Nguyen, T. V., Schneider, D., Sambrook, P. N., & Eisman, J. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09075-8 · Cited by 1,926 · cited 1×
“Osteoporotic fractures are a significant cause of morbidity and mortality, especially in the developed countries,(30) and are associated with increased mortality, particularly in men.(31)”
Predictive Value of BMD for Hip and Other Fractures
Johnell, O., Kanis, J. A., Oden, A., Johansson, H., De Laet, C., Delmas, P., Eisman, J. A., Fujiwara, S., Kroger, H., Mellstrom, D., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050304 · Cited by 1,445 · cited 1×
“A large meta-analysis, which included approximately 39 000 men and women, has concluded that the age-specific risk of hip fracture is similar in both men and women with the same BMD and age.(39) Despite these limitations, the results of BMD assessment suggest that the IDD population may have an increased risk for oste…”
ResultKatznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791
Effects of Testosterone Replacement in Hypogonadal Men1
Snyder, P. J., Peachey, H., Berlin, J. A., Hannoush, P., Haddad, G., Dlewati, A., Santanna, J., Loh, L., Lenrow, D. A., Holmes, J. H., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6731 · Cited by 572 · cited 1×
“BMD can be normalised and maintained within the normal range in men with either primary or secondary hypogonadism by continuous, long-term hormonal replacement therapy,(40) though the full effect on BMD may take up to 24 months.(41) Opioid-induced hypogonadism may be reversible.”
BackgroundThe effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564 · cited 2×
“sion to the patient when long-term opioid therapy is being considered.(12) Animal studies suggest that opioids affect gonadotropin”
BackgroundEndocrine consequences of long-term intrathecal administration of opioids
Abs, R., Verhelst, J., Maeyaert, J., Van Buyten, J.-P., Opsomer, F., Adriaensen, H., Verlooy, J., Van Havenbergh, T., Smet, M., & Van Acker, K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6615 · Cited by 491
Effects of Testosterone Replacement in Hypogonadal Men
Snyder, P. J. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2670 · Cited by 464
Petak, S. M., Nankin, H. R., Spark, R. F., Swerdloff, R. S., Rodriguez-Rigau, L. J., Anderson, R. J., Bergman, D. A., Garber, J. R., Hamilton Jr, C. R., Hershon, K. S., et al. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.439 · Cited by 372
Mellström, D., Johnell, O., Ljunggren, Ö., Eriksson, A.-L., Lorentzon, M., Mallmin, H., Holmberg, A., Redlund-Johnell, I., Orwoll, E., & Ohlsson, C. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060110 · Cited by 337
The impact of opioids on the endocrine system
Katz, N., & Mazer, N. A. (2009) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e3181850df6 · Cited by 307
Amin, S., Zhang, Y., Sawin, C. T., Evans, S. R., Hannan, M. T., Kiel, D. P., Wilson, P. W. F., & Felson, D. T. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-12-200012190-00010 · Cited by 293 · cited 1×
“No association between age-related hypogonadism (based on total testosterone) and decreased BMD was found in elderly men.(32) In contrast, free testosterone (calculated according to the Vermeulen equation) was demonstrated to be an independent predictor of BMD and fractures in elderly men(33) and a positive predictor…”
MethodThe endocrinology of the opiates and opioid peptides
Morley, J. E. (1981) · Metabolism · doi:10.1016/0026-0495(81)90172-4 · Cited by 283
Fracture risk associated with the use of morphine and opiates
VESTERGAARD, P., REJNMARK, L., & MOSEKILDE, L. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01667.x · Cited by 244
Onofrio, B. M., Yaksh, T. L., & Arnold, P. G. (1981) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(26)01499-0 · Cited by 240
Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids
Rajagopal, A., Vassilopoulou‐Sellin, R., Palmer, J. L., Kaur, G., & Bruera, E. (2004) · Cancer · doi:10.1002/cncr.20028 · Cited by 206 · cited 1×
“21 In a group of cancer survivors on opioids, 90% exhibited hypogonadism and low testosterone levels; LH levels, but not FSH levels, were found to be significantly lower when compared with cancer survivors not on opioid therapy.(22) The important role of endogenous opioids in the control of LH secretion has been demon…”
BackgroundBone mineral density in subjects using central nervous system-active medications
Kinjo, M., Setoguchi, S., Schneeweiss, S., & Solomon, D. H. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.07.033 · Cited by 191 · cited 1×
“istration and reduced BMD was demonstrated in one study but the presence or absence of hypogonadism was not assessed.(25) In a cross-sectional study, osteopaenia was present in 50% of the male patients undertaking oral opioids,(26) but again it was not clear if those patients were hypogonadal.”
BackgroundBernards, C. M. (2006) · Anesthesiology · doi:10.1097/00000542-200607000-00027 · Cited by 175 · cited 1×
“The drug is highly localised, so its analgesic efficacy is maximised at lower doses.(4) Moreover, opioid dose escalation over the years may be modest.”
Backgroundβ-Endorphin and dynorphin control serum luteinizing hormone level in immature female rats
Schulz, R., Wilhelm, A., Pirke, K. M., Gramsch, C., & Herz, A. (1981) · Nature · doi:10.1038/294757a0 · Cited by 170
Lorentzon, M., Swanson, C., Andersson, N., Mellström, D., & Ohlsson, C. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050404 · Cited by 159 · cited 1×
“In contrast, free testosterone (calculated according to the Vermeulen equation) was demonstrated to be an independent predictor of BMD and fractures in elderly men(33) and a positive predictor of cortical bone size in young men at the age of peak bone mass.(34) These contradictory findings may have occurred because fr…”
MethodOnofrio, B. M., Yaksh, T. L., Arnold, P. G., & Bridenbaugh, L. D. (1982) · Survey of Anesthesiology · doi:10.1097/00132586-198204000-00060 · Cited by 155
Hypogonadism in patients treated with intrathecal morphine
Finch, P. M., Roberts, L. J., Price, L., Hadlow, N. C., & Pullan, P. T. (2000) · The Clinical Journal of Pain · doi:10.1097/00002508-200009000-00011 · Cited by 144 · cited 2×
“control group of chronic pain patients who were not taking any form of opioid drugs.(24) Of the possible chronic illnesses identified in a longitudinal study with 890 male participants, only cancer (9%) was associated with a greater decrease in testosterone levels than the decrease that occurred with ageing alone.”
BackgroundPharmacokinetic Aspects of Intrathecal Morphine Analgesia
Nordberg, G., Hedner, T., Mellstrand, T., & Dahlström, B. (1984) · Anesthesiology · doi:10.1097/00000542-198405000-00010 · Cited by 143
Altered sexual function and decreased testosterone in patients receiving intraspinal opioids
Pake, J. A., Penn, R. D., & Ryan, W. G. (1994) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(94)90166-x · Cited by 140
Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency
Daniell, H. W., Lentz, R., & Mazer, N. A. (2006) · The Journal of Pain · doi:10.1016/j.jpain.2005.10.009 · Cited by 135 · cited 1×
“Clinically significant improvements in hypogonadal symptoms were observed in men with opioid-induced androgen deficiency following treatment with transdermal testosterone patches.(42) In patients undertaking intrathecal opioid delivery, recovery of serum testosterone levels following cessation of therapy or significan…”
BackgroundOral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women
Fraser, L.-A., Morrison, D., Morley-Forster, P., Paul, T., Tokmakejian, S., Larry Nicholson, R., Bureau, Y., Friedman, T., & Uum, S. H. M. V. (2008) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2008-1076715 · Cited by 112 · cited 1×
“Low libido and amenorrhoea have been reported in female IDDS patients,(17) 24 although the prevalence has been reported to be lower in women.(26) A large meta-analysis, which included approximately 39 000 men and women, has concluded that the age-specific risk of hip fracture is similar in both men and women with the…”
BackgroundSexuality and sexual adjustment of patients with chronic pain
Monga, T. N., Tan, G., Ostermann, H. J., Monga, U., & Grabois, M. (1998) · Disability and Rehabilitation · doi:10.3109/09638289809166089 · Cited by 103
Reddy, R. G., Aung, T., Karavitaki, N., & Wass, J. A. H. (2010) · BMJ · doi:10.1136/bmj.c4462 · Cited by 90 · cited 1×
“Currently, opioid-induced hypogonadism is under-recognised and undertreated.(8) 9 Some patients may attribute the signs and symptoms of hypogonadism, such as decreased libido, tiredness, loss of muscle mass and strength, among others, to the chronic pain and its related conditions rather than to the intrathecal medica…”
BackgroundSex hormone-binding globulin in osteoporosis
Hoppé, E., Bouvard, B., Royer, M., Audran, M., & Legrand, É. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.03.011 · Cited by 81 · cited 1×
“However, in middle-aged and elderly men, SHBG elevation was significantly associated with the occurrence of osteoporotic fractures.(36) Although not yet confirmed, it has been suggested that the effect of SHBG on BMD may change with age and/or testosterone sufficiency or deficiency.”
BackgroundHormonal and Biochemical Parameters and Osteoporotic Fractures in Elderly Men
Dr. Center, J. R., Nguyen, T. V., Sambrook, P. N., & Eisman, J. A. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.7.1405 · Cited by 77
Leung, W. Y. S., So, W., Tong, P. C. Y., Chan, N. N., & Chan, J. C. N. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.07.050 · Cited by 73
Predominant involvement of mu- rather than delta- or kappa-opiate receptors in LH secretion
Pfeiffer, D. G., Pfeiffer, A. F. H., Shimohigashi, Y., Merriam, G. R., & Loriaux, D. L. (1983) · Peptides · doi:10.1016/0196-9781(83)90012-8 · Cited by 68 · cited 1×
“release via the inhibition of the gonadotropin releasing hormone (GnRH) by β-endorphin,(13) most likely at the μ-receptors.(14) This inhibition reduces the release of the luteinising hormone (LH) and the follicle stimulating hormone (FSH) by the pituitary gland and consequently”
Opioid control of gonadotrophin secretion in humans
Genazzani, A. R., Genazzani, A. D., Volpogni, C., Pianazzi, F., Li, G. A., Surico, N., & Petraglia, F. (1993) · Human Reproduction · doi:10.1093/humrep/8.suppl_2.151 · Cited by 60
Sex Hormone Binding Globulin: Inhibitor or Facilitator (or Both) of Sex Steroid Action?
Khosla, S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1990 · Cited by 49 · cited 1×
“Although not yet confirmed, it has been suggested that the effect of SHBG on BMD may change with age and/or testosterone sufficiency or deficiency.(37) It is important to note the limitations of this study.”
Biochemical hypogonadism in men with type 2 diabetes in primary care practice
Hackett, G. I., Cole, N. S., Deshpande, A. A., Popple, M. D., Kennedy, D., & Wilkinson, P. (2009) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/1474651409342635 · Cited by 49 · cited 1×
“Serum TT 8–12 nmol/L and/or FT 180– 250 pmol/L were considered as borderline/low.(18)”
BackgroundLong-term Intrathecal Drug Administration for Chronic Nonmalignant Pain
Duarte, R. V., Raphael, J. H., Sparkes, E., Southall, J. L., LeMarchand, K., & Ashford, R. L. (2011) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0b013e31822ff779 · Cited by 44 · cited 1×
“Moreover, opioid dose escalation over the years may be modest.(5) 6 These factors lead to a decrease in the possible opioid side effects.”
BackgroundSelf-citationA Predictive Model for Intrathecal Opioid Dose Escalation for Chronic Non-Cancer Pain
Duarte, R. V., Raphael, J. H., Haque, M. S., Southall, J. L., & Ashford, R. L. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/363 · Cited by 35
Self-citationVanbillemont, G., Lapauw, B., Bogaert, V., Goemaere, S., Zmierczak, H., Taes, Y., & Kaufman, J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2189 · Cited by 30 · cited 1×
“Recently, it has been suggested that the SHBG levels in healthy adult men at the age of peak bone mass were positively associated with cortical bone size independent of the sex-steroid levels.(35) However, in middle-aged and elderly men, SHBG elevation was significantly associated with the occurrence of osteoporotic f…”
BackgroundDuarte, R. V., Raphael, J. H., Labib, M., Southall, J. L., & Ashford, R. L. (2013) · Pain Physician · doi:10.36076/ppj.2013/16/9 · Cited by 24
Self-citationCovington, E. C., & Mathews, M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6643-9.00149-1 · Cited by 12
Grady, K. M., & Raphael, J. H. (2008) · CRC Press eBooks · doi:10.1201/b13472-21 · Cited by 7
Self-citationSomori, G. J., Kallar, S. K., & Keenan, R. L. (1984) · Anesthesiology · doi:10.1097/00000542-198409001-00448 · Cited by 2
Research works printed but not linked: 1
- 7. Doleys D, Dinoff B, Page L, et al. Sexual dysfunction and other side effects of intraspinal opiate use in the management of chronic non-cancer pain. Am J Pain Manag 1998;8:5-11.
Cited by
Opioids and their endocrine effects: a systematic review and meta-analysis
de Vries, F., Bruin, M., Lobatto, D. J., Dekkers, O. M., Schoones, J. W., van Furth, W. R., Pereira, A. M., Karavitaki, N., Biermasz, N. R., & Zamanipoor Najafabadi, A. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz022 · Cited by 139
Coluzzi, F., Mattia, C., Raffa, R. R., & Pergolizzi, J. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s79409 · Cited by 77
“Usually, these effects are reversible, but chronic use may lead to serious symptoms when the diagnosis is missed.(31,32) The endocrine effects of opioids primarily include the inhibition of the hypothalamic, pituitary, and gonadal hormones, and hypothalamic–pituitary–adrenal axis T he ra pe ut ic s an d C lin ic al R…”
BackgroundOpioid-induced endocrinopathies
Fountas, A., Van Uum, S., & Karavitaki, N. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30254-2 · Cited by 77
Crosstalk between skeletal and neural tissues is critical for skeletal health
Abeynayake, N., Arthur, A., & Gronthos, S. (2020) · Bone · doi:10.1016/j.bone.2020.115645 · Cited by 67
Kotlińska-Lemieszek, A., & Zylicz, Z. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s342409 · Cited by 74
“Long-term use of opioids may result in decreased muscle mass and bone loss.(37,41)”
Metadata
- Authors
- Duarte, R. V., Raphael, J. H., Southall, J. L., Labib, M. H., Whallett, A. J., & Ashford, R. L.
- Affiliations
- Birmingham City University (GB)
- Russells Hall Hospital (GB)
- Corresponding author
- Duarte, Rui V
- ORCID
- Duarte, Rui V
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2013-05
- Volume
- 3
- Issue
- 6
- Pages
- e002856
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC3669726
- OpenAlex
- W2103038519
- Semantic Scholar
- b019604a80b5d8c73fb029af4f308e7797ca3f28
- Cited by
- 55
- References
- 47
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 5 · 2019: 8 · 2018: 3 · 2017: 2 · 2016: 6 · 2015: 3 · 2014: 6 · 2013: 1
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- hypogonadism, osteopenia, chronic non-cancer pain, osteoporosis, hypothalamic-pituitary-gonadal axis, free testosterone, luteinizing hormone, follicle-stimulating hormone, sex hormone-binding globulin, hip fracture risk, male patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.